TMEFF1 inhibitors belong to a distinctive class of chemical compounds that target and modulate the activity of transmembrane protein with epidermal growth factor and two follistatin motifs 1 (TMEFF1). TMEFF1, also known as tomoregulin-1, is a transmembrane protein that plays a role in cell signaling and is implicated in various cellular processes. The inhibitors specifically interact with TMEFF1, hindering its normal function within cellular pathways. These compounds typically act through mechanisms that involve binding to specific regions of the TMEFF1 protein, thereby disrupting its native conformation or impeding its interactions with other cellular components.
TMEFF1 inhibitors exhibit diverse chemical compositions, reflecting the versatility required to selectively modulate the target protein. Researchers have explored various scaffolds and molecular motifs to design compounds capable of effectively inhibiting TMEFF1 activity. The development of TMEFF1 inhibitors involves a meticulous understanding of the protein's structure and function, allowing for the rational design of compounds that interfere with its role in cellular processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
It can inhibit EGFR, a receptor known to interact with TMEFF1, thereby indirectly affecting TMEFF1 actions. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib is another EGFR inhibitor that can indirectly influence TMEFF1 function. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
It can inhibit both EGFR and HER2/neu, potentially affecting TMEFF1 signaling via these pathways. | ||||||
PD 184,352 | 212631-79-3 | sc-202759 sc-202759A | 1 mg 5 mg | $40.00 $260.00 | 34 | |
CI-1040 is a MEK inhibitor; since MEK is downstream of EGFR, inhibiting it can indirectly affect TMEFF1. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
This compound is a PI3K inhibitor, and PI3K is a part of the EGFR signaling pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that can indirectly affect TMEFF1. | ||||||
GDC-0941 | 957054-30-7 | sc-364498 sc-364498A | 5 mg 10 mg | $188.00 $199.00 | 2 | |
GDC-0941 is a potent inhibitor of PI3K, potentially influencing TMEFF1. | ||||||
BKM120 | 944396-07-0 | sc-364437 sc-364437A sc-364437B sc-364437C | 5 mg 10 mg 25 mg 50 mg | $176.00 $235.00 $281.00 $339.00 | 9 | |
BKM120 is another PI3K inhibitor that can affect TMEFF1 indirectly. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib is a MEK inhibitor, once more potentially affecting TMEFF1 indirectly via the EGFR pathway. | ||||||